Grifols, S.A. (NASDAQ:GRFS - Get Free Report) shares gapped up prior to trading on Friday . The stock had previously closed at $6.52, but opened at $6.81. Grifols shares last traded at $6.79, with a volume of 66,413 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Morgan Stanley initiated coverage on shares of Grifols in a research note on Wednesday, February 12th. They issued an "overweight" rating on the stock.
View Our Latest Report on GRFS
Grifols Stock Performance
The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. The company has a market capitalization of $4.81 billion, a P/E ratio of 5.98 and a beta of 0.41. The stock's fifty day moving average price is $7.49 and its 200-day moving average price is $7.85.
Institutional Trading of Grifols
Hedge funds have recently made changes to their positions in the business. Soleus Capital Management L.P. lifted its holdings in Grifols by 46.1% during the 4th quarter. Soleus Capital Management L.P. now owns 6,605,425 shares of the biotechnology company's stock valued at $49,144,000 after purchasing an additional 2,083,722 shares during the last quarter. Norges Bank acquired a new stake in shares of Grifols in the fourth quarter valued at approximately $14,434,000. JPMorgan Chase & Co. increased its stake in Grifols by 144.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company's stock worth $17,782,000 after acquiring an additional 1,181,959 shares during the period. Credit Industriel ET Commercial bought a new stake in shares of Grifols during the 4th quarter valued at $4,537,000. Finally, Brandes Investment Partners LP increased its position in shares of Grifols by 3.0% in the fourth quarter. Brandes Investment Partners LP now owns 20,496,093 shares of the biotechnology company's stock worth $152,491,000 after purchasing an additional 592,096 shares during the period.
Grifols Company Profile
(
Get Free Report)
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
See Also
Before you consider Grifols, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.
While Grifols currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
